AUTL
Autolus Therapeutics plc
$2.41
-2.03%
2026-08-21
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Key Fundamentals
Forward P/E
-3.39
EPS (TTM)
$-1.06
ROE
-29.6%
Profit Margin
0.0%
Debt/Equity
122.50
Price/Book
0.36
Beta
1.99
Market Cap
$572.2M
Avg Volume (10D)
4.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.58
60D Low
$1.38
Avg Volume
1.9M
Latest Close
$2.41
Get breakout alerts for AUTL
Sign up for Breakout Scanner to receive daily notifications when AUTL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Autolus Therapeutics plc (AUTL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AUTL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AUTL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.